Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIT-E: Vatiquinone for Refractory Epilepsy in Mitochondrial Disease
NCT04378075Phase 3Terminated
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Sep 2020
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of vatiquinone in mitochondrial disease, epilepsy, sponsored by PTC Therapeutics, Inc.. Started Sep 2020; status: terminated.
02
Drugs
vatiquinone
03
Conditions
mitochondrial diseaseepilepsy
Beyond the preview
Go deeper on NCT04378075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04378075.